Unveiling the cancer epidemic in India: a glimpse into GLOBOCAN 2022 and past patterns.

Lancet Reg Health Southeast Asia

Division of Implementation Research, Indian Council of Medical Research (ICMR), Headquarters, New Delhi, 110029, India.

Published: March 2025

Background: The Global Cancer Observatory (GLOBOCAN) 2022 estimates highlight cancer as a significant global health problem. In the South-East Asia-region, India ranks third in terms of cancer incidence, second for mortality, and 121 in terms of crude rates globally. As cancer risks increase with age, particularly affecting older individuals, this study explores the current cancer burden in India by analyzing the cancer landscape across different age groups, determining the population's risk of cancer diagnosis and death, and projecting the future cancer burden aligned with past mortality patterns.

Methods: This is a comprehensive-retrospective, cross-sectional study examining 36 cancer types, by gender, and across four-distinct age groups (childhood, reproductive, middle age, geriatric) in India, using the GLOBOCAN 2022 database. The study further analyzes the past mortality patterns (2000-2022) and future cancer landscape of India by determining annual percent change (APC), through Multijoinpoint regression analysis.

Findings: The five most prevalent cancers affecting both genders collectively account for 44% of cancer burden in India. Notably, females exhibit higher crude incidence (104.5) and crude mortality (64.2) rates compared to males (91.5 and 62.2), based on 0.676 billion females and 0.731 billion males' populations in 2022. The middle-aged and geriatric-cohorts account the heaviest (70%) cancer burden with higher crude rates (315.9-543.1 incidents, 215.6-407.8 mortalities). Alarmingly, cancer-related mortalities have increased faster among females (1.2-4.4% APC) than males (1.2-2.4% APC) over the past decade, and are expected to continue rising over coming two decades.

Interpretation: Approximately three out of every five individuals in India succumb to death following a cancer diagnosis, as per the GLOBOCAN 2022 incidence (1,413,316) to mortality (916,827) ratio. Childhood and reproductive age-group individuals bear the lowest risk of developing (0.12-2.4%) and dying (0.08-1.3%) from cancer compared to their middle-aged and geriatric counterparts, having highest risks of developing (8.3-10.3%) and dying (5.5-7.7%) from cancer. As the population of India transitions from the reproductive age group to the middle age and geriatric age group, the India is anticipated to witness the highest cancer burden of all-time in near future, potentially exacerbated by the looming epidemic.

Funding: No funding received.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893321PMC
http://dx.doi.org/10.1016/j.lansea.2025.100546DOI Listing

Publication Analysis

Top Keywords

cancer burden
20
globocan 2022
16
cancer
16
india
9
crude rates
8
burden india
8
cancer landscape
8
age groups
8
cancer diagnosis
8
future cancer
8

Similar Publications

Historical studies performed nearly a century ago using mouse skin models identified two key steps in cancer evolution: initiation, a likely mutational event, and promotion, driven by inflammation and cell proliferation. Initiation was proposed to be permanent, with promotion as the critical rate-limiting step for cancer development. Here, we carried out whole genome sequencing to demonstrate that initiated cells with thousands of mutagen-induced mutations can persist for long periods and are not removed by cell competition or by immune intervention, thus mimicking the persistence of cells with cancer driver mutations in normal human tissues.

View Article and Find Full Text PDF

Introduction: Cases of warm autoimmune hemolytic anemia (wAIHA) often present with life-threatening levels of hemoglobin requiring red blood cell (RBC) transfusion support.

Aim: This literature review assessed the occurrence, safety, effectiveness, and hospitalization burden of RBC transfusions in the management of patients with wAIHA.

Methods: Electronic databases (Embase, MEDLINE) were searched from inception to December 2021 along with additional searches conducted up to March 2024.

View Article and Find Full Text PDF

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS inhibitor in KRAS LUAD.

Proc Natl Acad Sci U S A

March 2025

Laboratorio 1. Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas-Universidad de Salamanca and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Salamanca 37007, Spain.

We evaluated the in vivo therapeutic efficacy and tolerability of BI-3406-mediated pharmacological inhibition of SOS1 in comparison to genetic ablation of this universal Ras-GEF in various KRAS-dependent experimental tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2 mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. Allograft assays using different KRAS cell lines showed that treatment with BI-3406 impaired RAS activation and RAS downstream signaling and decreased tumor burden and disease progression as a result of both tumor-intrinsic and -extrinsic therapeutic effects of the drug.

View Article and Find Full Text PDF

Purpose: The primary purpose was to assess the feasibility and acceptability of a group health coaching (GHC) program with cancer patients and survivors; secondarily, to determine the preliminary effects of GHC on several behavioral lifestyle factors.

Methods: GHC was provided to people diagnosed with cancer via videoconference by trained health coaches across six GHC sessions over a 3-month period. Qualitative and quantitative data were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!